Post on 27-Mar-2018
Inpatient Antimicrobial Stewardship Program Implementation
Kendall Van Tyle, PharmD, BCPS, ASP Chair
Northern Navajo Medical Center
Objectives
Define antimicrobial stewardship
Cite reasons why inpatient antibiotic stewardship programs(ASP) are important
Recall time-line and key milestones for implementation ofI.H.S. ASP for inpatient
Compare & contrast examples of ASP elements
List potential starting points for ASP implementation foryour site
List some resources available
Stewardship
“The management or care for something, particularly the kind that is successful”
The Goal
Prospective optimization of antibiotic therapy – period.
Antimicrobial Stewardship
Strategic efforts to optimize antimicrobial prescribing
Drug
Dose
Duration
De-escalation
Indication - recognize when not needed
Something To Ponder
Antibiotic stewardship asks us to think about thecommunity, not only the patient being treated
The adverse effects of antibiotic overuse and misuse haveimplications beyond the patient and outside of your facility
Why Implement ASP?
“If best infection control practices and antibiotic stewardship were nationally adopted, more than 600,000 infections and 37,000 deaths could be prevented over 5
years.”
MMWR / August 4, 2015 / Vol. 64
CDC Emerging Infections Program (EIP) Assessment of Prescribing in 36 Hospitals
Antibiotic prescribing could potentially be improved in over onethird (37%) of common prescription scenarios
Examples:
“UTI” – Asymptomatic bacteria accounted for 21% of patientsreceiving treatment with antibiotics
Vancomycin use• No Gram (+) bacterial growth, but still treated >3 days: 22%
• Culture grew only oxacillin-susceptible Staphylococcus aureus, butpatient still treated >3 days : 5%
Fridkin et al. MMWR. 2014:63(09);194-200
Rationale For Antibiotic Stewardship
Improve Patient Care and Safety Prevent C. Difficile infections
Minimize Adverse Events
Reduce Resistance Preserve antimicrobial effectiveness
Decrease excess deaths
Recommends that a regulatory requirement for antibiotic stewardship be in place by 2017
https://www.whitehouse.gov/sites/default/files/microsites/ostp/PCAST/pcast_carb_report_sept2014.pdf
As California Goes….
“Starting July 1 (2015), acute care hospitals in California must put into effect antimicrobial stewardship programs…….”
http://www.ashp.org/menu/News/PharmacyNews/NewsArticle.aspx?id=4174#sthash.70TCbofW.dpuf
https://www.cms.gov/Medicare/Provider-Enrollment-and-Certification/SurveyCertificationGenInfo/Downloads/Survey-and-Cert-Letter-15-12-Attachment-1.pdf
“No Citation Risk – Information Only”
1.C.9 -The hospital has written policies...
1.C.10 – The hospital has designated a leader…
1.C.11 – Requires an indication for all antibiotic orders
1.C.12 – Formal requirement of antibiotic “time out’ at 48h
1.C.13 – Monitors consumption of antibiotics…
https://www.cms.gov/Medicare/Provider-Enrollment-and-Certification/SurveyCertificationGenInfo/Downloads/Survey-and-Cert-Letter-15-12-Attachment-1.pdf
2012 Pilot by CMS
1.C.2.a Facility has a multidisciplinary process in place to review antimicrobial utilization, local susceptibility patterns, and antimicrobial agents in the formulary...
1.C.2.b Systems are in place to prompt clinicians to use appropriate antimicrobial agents….
1.C.2.e. The facility has a system in place to identify…..(Patients eligible for IV to PO)
https://www.cms.gov/Medicare/Provider-Enrollment-and-Certification/SurveyCertificationGenInfo/Downloads/Survey-and-Cert-Letter-12-32.pdf
Current Regulatory Need
CMS lack of payment for hospital acquired infections – these are deemed preventable
The Joint Commission Reduce risk of HAI’s
Implement strategies to reduce transmission of MDROs
NHSN event reporting for C. difficile
Proposed Timeline“Rome was not built in a day”
Implementation Timeline
• Goal is full implementation within 3 years
• Follow the Core Elements of Hospital Antibiotic StewardshipPrograms outlined by the CDC as a guide
Available at:
http://www.cdc.gov/getsmart/healthcare/implementation/core-elelments.html
• Goals for each year are flexible
Year 1 Goals
• Leadership Support
• Physician & Pharmacist Champions
• Policies & Procedures
• Antibiogram Development
• Antimicrobial Stewardship Education Program
Year 1 – Leadership Support
• Critical for success of ASP
• Formal statements of support
• Addition of stewardship activities on PMAPs and COERs
• Supporting training and education
• Ensuring participation from the various differentdepartments involved in ASP• Form an ASP workgroup/committee
• Obtaining financial support
Year 1 – Physician/Pharmacy Champions
• Identify physician champion• Training in infectious diseases/ASP beneficial
• Can leverage telemedicine
• Hospitalists may be ideal secondary to increasing presence in inpatient care
• Identify pharmacist champion• Training in infectious diseases/ASP beneficial
• The Pharmacy and Therapeutics committee should NOT be considered the stewardship team
Year 1 (cont.)
• Policies & Procedures (Examples)• Define the ASP Committee as a required committee for the hospital
• Identify required members
• Outline committee charges
• Identify frequency of meetings
• Document dose, duration, and indication
• Facility specific treatment recommendations
• Identify reporting requirements• Ex. Reports to P&T and/or medical staff
• Avoid implementing too many policies and interventionssimultaneously
Year 1 (cont.)
• Antibiogram Development• Done at least yearly for facility
• Can be done more often if need identified
• Can be done for individual hospital units if need identified• Ex. ICU, Burn Ward
• Follow best practices• Discussed later
Year 1 cont.
• Antimicrobial Stewardship Education Program• Include reasons for starting ASP
• Describe increasing resistance
• Describe best practices in treatment of infectious diseases
• View as a process, not an event• Continuous
• Multiple approaches
Year 2 Goals
• Guideline development
• Implementation of Interventions
• Development of Tracking Measures
• Continue ASP Education
Year 2 cont.
• Guideline development• For specific indications/disease states
• EHR indication specific order sets• CAP/HCAP
• MDROs
• UTI
• Cellulitis/Diabetic Foot
• MDROs
• C. Diff
• Treatment of culture proven invasive infections
Year 2 cont.
• Implementation of Interventions• Broad Interventions
• Antibiotic “time outs”
• Prior authorization
• Prospective audit and feedback
• Pharmacy-driven Interventions• Auto IV to PO conversions
• Dose adjustments (ex. Renal adjustment)
• Dose optimization
• Automatic alerts where therapy might be unnecessarily duplicative
• Auto-stop orders
• Detection and prevention of ABX-related DDI
Year 2 cont.
• Development of Tracking Measures• Monitoring Antibiotic Prescribing
• Monitor adherence to documentation policy (dose, duration, and indication)
• Monitor adherence to facility-specific treatment recommendations
• Monitor compliance with one or more of the specific interventions
• Antibiotic Use and Outcome Measures• Track C. difficle infections
• Produce an antibiogram report
• Monitor use by Days of Therapy, Defined Daily Dose, and/or direct expenditure
Implementation TimelineYear 3
• Year 3 Goals• Reporting of Intervention Results
• Reporting Information to Staff on Improving Antibiotic Use andResistance
• Continue ASP Education
Year 1 – Foundational Project
• Create an antibiogram if none exists
• Update existing antibiogram
• Review “best practices” checklist
Obtain Raw Data
• Work with microbiology lab supervisor
• Obtain report of susceptibility results for a given time frame,usually 1 calendar year
• Use “best practices” check list at this stage to eliminateduplicate isolates and validate data
Present Data
• Will usually need to transcribe data into a more userfriendly format• PDF – posted in E.H.R.
• Pocket Card
• Review “best practices” check list at this stage tovalidate/present data appropriately
Antibiogram Checklist
Adapted from:• Hindler JR, Stelling J. Analysis and presentation of cumulative antibiograms:
a consensus guideline from the Clinical and Laboratory Standards Institute.CID. 2007;44:867-73.
• Boehme MS, Somsel PA, Downes FP. Systematic review of antibiograms: anational laboratory systems approach for improving antimicrobialsusceptibility testing practices in Michigan. Pub H Rep. 2010;125(sup. 2):63-72.
Year 1 - Suggestions
• Consider simply documenting what pharmacy alreadydoes/sees• Can be used for hypothesis generation
• Might reveal some “low-hanging fruit”
• Lead to ASP interventions/policies in year 2 and beyond
• Find those in your organization already involved in qualitymeasures
Year 2 – Foundational Project
• Creation of local antibiotic use guidelines• Focus on common indications for facility
• Use antibiogram data and national guidelines
• Highly recommended to adapt these to Electronic HealthRecord, if possible
Year 2 Suggestions
• Consider your guidelines/E.H.R menus as an intervention
• Define and collect some baseline measures/data• Orders for XX drug for YY indication
• Survey prescriber use of guidelines/menus
• Recollect data at some point post intervention
• Repeat this process for every intervention identified andimplemented
Year 3 - Suggestions
• Review what worked and what didn’t
• Develop a process for continuous qualityimprovement• If an intervention succeeded, how to sustain it
• If it didn’t – why?• Evaluate variables defined and measured; methods
• Evaluate process
• PDSA cycles• Plan, Do, Study, Act – repeat.
Metrics
Options
Type Metric Definition
• Defined Daily Doses(DDD)
• Total Grams antibiotics useddivided by WHO approved DDDvalues
Consumption
• Grams• Total Grams used from
administered, dispensed, orpurchased data sources/reports
• Days of Therapy (DOT)• Number of days that the patient
receives at least one dose of anantibiotic
• Length of Therapy (LOT)• Number of days that the patient
receives therapy regardless ofnumber of drugs or doses received
• Expenditures • Dollars spent
Options
Type Metric Definition
Patient Outcomes• Health Care Associated
Infections
• Rate of disease-specific infections (e.g.C. Diff, MRSA, VAP)
• ASP Intervention rates• ASP Intervention Acceptance rates
Resistance • Antibiotic Resistant Organisms
• % of patients with resistant organism(s)• Antibiogram data• % of isolates of a pathogen with
antibiotic resistance
Advantages vs Disadvantages
Metric Advantage(s) Disadvantage(s)
Defined Daily Dose (DDD)
• Easy to calculate• Can be utilized as a
“benchmark” betweenhospitals, regions, andcountries
• Never intended to be used as ametric to study ASP impact
• Biases against combination therapy,even when that therapy might be anarrower spectrum
• Assumes routine dosing –“penalized” if using clinicallyappropriate higher or lower dosing
• Not applicable to pediatrics
Grams
• Purchase data easy to obtain• Not affected by price
fluctuations• Can be used to calculate DDD
• Purchase data is the least accurate
Advantages vs Disadvantages
Metric Advantage(s) Disadvantage(s)
Days of Therapy (DOT)
• Offers more clinical relevancethan DDD
• Applicable to pediatrics• Recommended by CDC, US
National Healthcare SafetyNetwork
• Difficult to obtain data• Not applicable to renal population• Incentivizes the use of broad
spectrum monotherapy• A patient receiving 2 antibiotics for 7
days = 14 DOTs
Length of Therapy (LOT) “Treatment Period”
• Most reflective of actualtreatment duration
• Accounts for dosing intervalsbeyond 1 day (i.e. Q48HVancomycin)
• Does not penalize programs forchanging antibiotics based uponC&S results
• Cannot be used to compare the use ofspecific drugs
Expenditures (Cost of Therapy)
• “Easiest” metric to calculate andobtain data for
• Easily understood by all
• Affected by cost variations; natural orotherwise
• Affected by changes in formulary• Should not be used for benchmarking
purposes due to cost variability
Advantages vs Disadvantages
Metric Advantage(s) Disadvantage(s)
Antimicrobial-free Days
• Avoids issues related to Broad vs Narrowspectrum therapy
• Avoids issues related to Mono- vs Duo-Therapy
• Focuses on whether patients arereceiving an antibiotic or not
• Mostly used as a disease-specific consumption measure(i.e. ventilator-associatedpneumonia)
Point Prevalence“Snapshot” Surveys
• Resource-efficient• Typically done at a single site on a single
day• Data collected may include % patients
prescribed antibiotics, % “restricted”antibiotics prescribed, # antibiotics perpatient, duration of therapy, dosing anddosage interval, time for IV to PO switch
• Can be used to measure and compareantibiotic use at multiple sites
• Can only provide feedback onlimited elements of prescribing
• May not consistently reflecttypical practice within a Unit orHospital
Using Bar Coded Medication Administration Data (BCMA)
Paper published by the VA in 2012
Compares BCMA vs. Orders data
Used to help calculate some of the metrics described
NHSN AU Modulehttp://www.cdc.gov/nhsn/PDFs/training/AUR-training.pdf
Infect Control Hosp Epidemiol 2012;33(4):4090411
BCMA Log Output - RPMS
“Crunched” Data –Days of Therapy
ASP Resources
• CDC• http://www.cdc.gov/getsmart/healthcare/implementation.html
• IDSA/SHEA• http://www.idsociety.org/Stewardship_Policy/#sthash.gZe2Eucl.dpuf
• ASHP• http://www.ashp.org/menu/PracticePolicy/ResourceCenters/Inpatient-
Care-Practitioners/Antimicrobial-Stewardship
Additional Resources
• I.H.S. ASP Workgroup members
• I.H.S. ASP Listserv
• Antibiogram Checklist
• Metric Databases (RPMS)
• PDSA forms
• Cited References
IHS NPC ASP Workgroup Members
• Dr. Daniel Marino: Daniel.Marino@ihs.gov Phone: 520-295-2401
• Robin Bartlett: Robin.Bartlett@ihs.gov Phone: 615-467-1577
• Shani Bjerke: Shani.Bjerke@ihs.gov Phone: 218-679-3912
• Linda Crosby: Linda.Crosby@ihs.gov Phone: 541-553-2134
• Jeff Gildow: Jeffrey.Gildow@ihs.gov Phone: 402-878-2231
• Tim Langford: tglangford@klm.portland.ihs.gov
Phone: 541-882-1487 x354
• Chris McKnight: Christopher.McKnight@cherokeehospital.orgPhone: 828-497-9163 x6379
• Jodi Tricinella: Jodi.Tricinella@ihs.gov Phone: 918-342-6298
• Kendall Van Tyle: Kendall.VanTyle@ihs.gov Phone: 505-368-7250
• Thaddus Wilkerson: tdwilkerson@anthc.org Phone: 907-729-2155
• Ron Won: Roney.Won@ihs.gov Phone: (503) 414-5579
• Jon Schuchardt: Jon.schuchardt@ihs.gov Phone: (605) 355-2281
56
Conclusions/Pep Talk
• Implementation is important• Think “patient safety”
• Think “public health”
• Implementation is easy• Take it one step at a time
• One step will lead to the next
• Implementation is rewarding• Impact and positive change
• Do something today.